Iron overload – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:30 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Iron overload – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Safety and Tolerability of REGN7999 in Healthy Adult Participants https://clinicaltrials.eu/trial/safety-and-tolerability-of-regn7999-in-healthy-adult-participants/ Wed, 29 Apr 2026 15:08:55 +0000 https://clinicaltrials.eu/trial/safety-and-tolerability-of-regn7999-in-healthy-adult-participants/ The study looks at a medicine called REGN7999, which works by blocking a protein named TMPRSS6. This type of medicine is being developed for conditions where the body stores too much iron, known as iron overload. In the trial the drug is given in two ways: through a needle into a vein (intravenous) or under the skin (subcutaneous), and the amount given is increased step by step to see how the body handles it.

The purpose of the trial is to find out if a single dose of REGN7999 is safe and well tolerated in healthy adult volunteers. Participants are randomly assigned to receive either the medicine or a placebo, and neither the participants nor the study staff know which one is given. After the dose, participants are checked regularly for any side effects, and blood samples are taken to measure how much of the medicine is in the blood and whether the immune system makes any antibodies against it. The follow‑up period lasts up to about five to six months, depending on the group, with visits scheduled to monitor health and collect samples.

]]> Study on the Use of Human Apotransferrin for Treating Patients with Atransferrinemia https://clinicaltrials.eu/trial/study-on-the-use-of-human-apotransferrin-for-treating-patients-with-atransferrinemia/ Wed, 29 Apr 2026 15:01:04 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-human-apotransferrin-for-treating-patients-with-atransferrinemia/ This clinical trial is focused on studying a rare blood disorder called atransferrinemia. Atransferrinemia is a condition where the body has very low levels of a protein called transferrin, which is important for transporting iron in the blood. The treatment being tested in this study is called Human Apotransferrin, which is given as a solution through an intravenous infusion. This means the treatment is delivered directly into the bloodstream through a vein.

The purpose of the study is to evaluate how the body processes Human Apotransferrin, as well as its effectiveness and safety in treating atransferrinemia. Participants in the study will receive different doses of Human Apotransferrin to find the most effective and safe dose. The study will monitor changes in important blood components, such as hemoglobin and hematocrit, which are indicators of healthy blood function. It will also look at how the treatment affects iron levels in the body, including the liver and heart, to ensure there is no iron overload.

Throughout the study, participants will have regular check-ups to assess their response to the treatment and to monitor any side effects. The study aims to improve the understanding of how Human Apotransferrin can help manage atransferrinemia and improve the quality of life for those affected by this condition.

]]>